Michael Sprakes

Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: A large single centre experience

Michael Sprakes, Alexander C. Ford, Lisa Warren et al. · Journal of Crohn s and Colitis · 2011 · 157 citations · Full text

Pharmacy, Clinical Sciences, Pharmacotherapy +17

Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab

Simeng Lin, Nicholas A. Kennedy, Aamir Saifuddin et al. · Nature Communications · 2022 · 81 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Costs of care for Crohn’s disease following the introduction of infliximab: a single‐centre UK experience

Michael Sprakes, Alexander C. Ford, N. C. Suares et al. · Alimentary Pharmacology & Therapeutics · 2010 · 36 citations

Pharmacy, Pharmacoeconomics, Pharmacotherapy +15

Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study

Zhigang Liu, Kaixing Le, Xin Zhou et al. · ˜The œLancet. Gastroenterology & hepatology · 2022 · 35 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Infliximab and surgical treatment of complex anal Crohn’s disease

Sarah Duff, P. M. Sagar, Sarah Dolling et al. · Colorectal Disease · 2011 · 26 citations

Medicine, Clinical Sciences, Surgery +15